BioSpace

UPDATE: Novo Nordisk Seeks To Steal Metsera From Pfizer With $8.5B Offer

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

Pfizer Responds to Delaware Chancery Court Ruling

Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc.

Pfizer poised to buy Metsera in $10 bn deal after bidding war

Pfizer was poised to seal a takeover of Metsera on Saturday after its improved offer won over the biotechnology startup's ...

Pfizer, Novo again raise Metsera bids in intensifying obesity drug battle

The Pfizer and Novo Nordisk battle for obesity drug developer Metsera intensified on Thursday after a fresh round of ...
BioSpace

UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid

Pfizer has filed two separate lawsuits in an effort to stop Novo Nordisk's unsolicited bid to acquire obesity biotech Metsera ...

Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of ...